Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future

Pioneering studies conducted in the 1980’s laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly establis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Wilfredo Mellado, Sari Hannila
Formato: Online
Idioma:inglês
Publicado em: Frontiers Media SA 2021
Assuntos:
Acesso em linha:24012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
_version_ 1869524202549149696
author Wilfredo Mellado
Sari Hannila
author_browse Sari Hannila
Wilfredo Mellado
author_facet Wilfredo Mellado
Sari Hannila
author_sort Wilfredo Mellado
collection Directory of Open Access Books
description Pioneering studies conducted in the 1980’s laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly established myelin as a key factor in regenerative failure. Mechanistically, it has been shown that MAG, Nogo, and OMgp mediate inhibition by binding to either Nogo receptor (NgR) or paired immunoglobulin receptor B (PirB), and initiating a signaling cascade that culminates in the activation of RhoA. Since the discovery of these proteins, there has been tremendous interest in identifying compounds and molecular mechanisms that are capable of overcoming myelin-mediated inhibition. Many studies have focused on pharmacological antagonism of receptors and signaling intermediates, while others have sought to identify and enhance endogenous pro-regenerative pathways. The most notable example of the latter is the conditioning lesion effect, which led to the discovery of cyclic AMP’s ability to overcome inhibition by MAG and myelin. Many of the agents tested in these studies have been shown to promote axonal regeneration in vivo, and this research topic allows researchers to share information about new treatments that have been developed in both academia and industry. As we look toward the future, it is becoming increasingly clear that reversal of myelin-mediated inhibition alone will not be sufficient to produce functional recovery from spinal cord injury, and that other factors, such as astroglial scarring, the expression of chondroitin sulfate proteoglycans, neuronal cell death, and lack of neurotrophic support, must also be taken into consideration. Combinatorial approaches therefore hold a great deal of promise, and we hope to initiate a dialogue on how stem cell transplantation, chondroitinase ABC, gene therapy, growth-promoting agents, and other methods can be combined to optimize functional recovery. We introduce this topic in honor of the life and work of Dr. Marie T. Filbin (1955-2014). Through these articles, we highlight past achievements in the field, novel findings, unanswered questions and innovative ideas that we hope will lead to new advances in axonal regeneration.
format Online
id doab-20.500.12854ir-54180
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher Frontiers Media SA
publisherStr Frontiers Media SA
record_format ojs
spelling doab-20.500.12854ir-541802024-04-05T17:30:45Z Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future Wilfredo Mellado Sari Hannila RC321-571 Q1-390 MAG Omgp axonal regeneration myelin-associated inhibitors CNS regeneration Nogo cAMP thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences Pioneering studies conducted in the 1980’s laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly established myelin as a key factor in regenerative failure. Mechanistically, it has been shown that MAG, Nogo, and OMgp mediate inhibition by binding to either Nogo receptor (NgR) or paired immunoglobulin receptor B (PirB), and initiating a signaling cascade that culminates in the activation of RhoA. Since the discovery of these proteins, there has been tremendous interest in identifying compounds and molecular mechanisms that are capable of overcoming myelin-mediated inhibition. Many studies have focused on pharmacological antagonism of receptors and signaling intermediates, while others have sought to identify and enhance endogenous pro-regenerative pathways. The most notable example of the latter is the conditioning lesion effect, which led to the discovery of cyclic AMP’s ability to overcome inhibition by MAG and myelin. Many of the agents tested in these studies have been shown to promote axonal regeneration in vivo, and this research topic allows researchers to share information about new treatments that have been developed in both academia and industry. As we look toward the future, it is becoming increasingly clear that reversal of myelin-mediated inhibition alone will not be sufficient to produce functional recovery from spinal cord injury, and that other factors, such as astroglial scarring, the expression of chondroitin sulfate proteoglycans, neuronal cell death, and lack of neurotrophic support, must also be taken into consideration. Combinatorial approaches therefore hold a great deal of promise, and we hope to initiate a dialogue on how stem cell transplantation, chondroitinase ABC, gene therapy, growth-promoting agents, and other methods can be combined to optimize functional recovery. We introduce this topic in honor of the life and work of Dr. Marie T. Filbin (1955-2014). Through these articles, we highlight past achievements in the field, novel findings, unanswered questions and innovative ideas that we hope will lead to new advances in axonal regeneration. 2021-02-11T20:26:55Z 2021-02-11T20:26:55Z 2017-10-13 14:57:01 2017 book 24012 16648714 9782889452064 https://directory.doabooks.org/handle/20.500.12854/54180 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Myelin-Mediated_Inhibition_of_Axonal_Regeneration_Past_Present_and_Future/1239 http://journal.frontiersin.org/researchtopic/3378/myelin-mediated-inhibition-of-axonal-regeneration-past-present-and-future Frontiers Media SA 10.3389/978-2-88945-206-4 10.3389/978-2-88945-206-4 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889452064 116 open access
spellingShingle RC321-571
Q1-390
MAG
Omgp
axonal regeneration
myelin-associated inhibitors
CNS regeneration
Nogo
cAMP
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences
Wilfredo Mellado
Sari Hannila
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
title Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
title_full Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
title_fullStr Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
title_full_unstemmed Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
title_short Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
title_sort myelin mediated inhibition of axonal regeneration past present and future
topic RC321-571
Q1-390
MAG
Omgp
axonal regeneration
myelin-associated inhibitors
CNS regeneration
Nogo
cAMP
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences
topic_facet RC321-571
Q1-390
MAG
Omgp
axonal regeneration
myelin-associated inhibitors
CNS regeneration
Nogo
cAMP
thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences
url 24012
work_keys_str_mv AT wilfredomellado myelinmediatedinhibitionofaxonalregenerationpastpresentandfuture
AT sarihannila myelinmediatedinhibitionofaxonalregenerationpastpresentandfuture